newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

  • Abeona Therapeutics Inc. management will participate in three investor conferences in September 2026.
  • The company will hold a fireside chat & investor meetings at the Cantor Global Healthcare Conference 2026 on September 9, 2026, at 8:00 a.m. ET.
  • Abeona will present & hold investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 12:00 p.m. ET.
  • The company will participate in a fireside chat & investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 11:30 a.m. ET.
  • Live webcasts & limited-time replays of these events are available on the Abeona Investors website under the "Events" section.
  • Abeona is a commercial-stage biopharmaceutical company developing cell & gene therapies for serious diseases.
  • ZEVASKYN is the first autologous cell-based gene therapy for wounds in adult & pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
  • The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, for ZEVASKYN commercial production.
  • Abeona's development portfolio includes ABO-701, a potentially first-in-class engineered T-cell therapy targeting PSMA to address solid tumors.